Authors
Latest:
AI and Benefit Verification: Providing Faster Access to MedicinesBenefit verification (BV) provides a detailed understanding of out of pocket costs for the prescribed treatment. Amy Jones details how AI is aiding the BV process.
Latest:
Enabling a Single Integrated View of Critical Real-World Data with Analytics as a ServiceAnalytics as a service can provide critical accelerators for the commercial transformation program at a life sciences organization, writes Himanshu Jain.
Latest:
What Natural Language Processing Can Do for Pharmacos: 3 Real-World Use CasesMany real-world data sources contain unstructured text, making it difficult and time-consuming to glean actionable insights from the data. Natural language processing technology can alleviate this problem, writes Jane Z. Reed.
Latest:
Navigating the Increasing Complexity of Drug-Biomarker Co-DevelopmentTo succeed in developing targeted medicines, companies need a biomarker strategy and the expertise to make smart decisions about clinical trial design, assays, technology platforms and collaborative partners, write Barry S. Sall and Angela X. Qu.
Latest:
Improving Management of Gene and Cell TherapiesAn overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Latest:
Improving Management of Gene and Cell TherapiesAn overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Latest:
Aligning Contracting to Solve for Payer Risks Is a Win for Biopharma, Payers, and PatientsUpcoming regulatory changes to create new opportunity for specialized offerings.
Latest:
Improving Management of Gene and Cell TherapiesAn overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Latest:
Improving Management of Gene and Cell TherapiesAn overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Latest:
Five Features to Ensure Lab-ready BuildingsA list of five essential features a building must have in order to be considered lab-ready.
Latest:
The ‘Spare-No-Expense’ AlternativeHow low-cost drugs can succeed in the specialty pharmacy channel.
Latest:
Aligning Tactics with the Goals of Value-Based CareThe marketing challenge for pharmaceutical companies has now shifted to "How can we successfully and cost-effectively assist providers in orchestrating better care?" William Febbo reports.
Latest:
Building Healthcare's "Ground Truth" with AIFor pharma leaders, AI can bring about a new reality of seeing a multitude of possible paths, forecasting the interplay of multi-dimensional trends, and charting patient journeys that are based on reality, writes Aswin Chandrakantan.
Latest:
Small Biotechs Gain As the Span of Clinical Trial Outsourcing GrowsSmall biotech companies benefit more from partnering with CROs rather than hiring a chief medical officer.
Latest:
Learning, Retaining, Applying Information: Preparing Reps for Success in the FieldThee most effective way to train sales reps and boost their success is to consider the learner/user experience in all facets, in every training encounter, and on each training platform, writes Shaun McMahon.
Latest:
Is Pharma Losing the Centerpiece of Its Market Access Toolbox?With employers and the public scrutinizing drug prices like never before, rebates-long at the center of pharma’s market access strategy-may be losing their luster, writes Amber Gilbert.
Latest:
How DSCSA Changes the Licensing LandscapeA look at the Drug SUpply Chain Security Act and how it impacts serialization and third-party logistics licensing.
Latest:
Closing Pharma’s Digital DivideOvercoming the challenges of digital brand management will involve choices in spending and channels.
Latest:
Managing Local Language Regulatory SubmissionsThe call to reduce market entry times for life-saving new drug therapies is becoming more urgent. What constitutes best practice in managing translations in today’s regulatory affairs environment? Nancy Pollini reports.
Latest:
What the Age of Multi-Localism Means for PharmaNew realities are transforming the global environment and upending a business model based on the presumption of ever more connected markets. Paul A. Laudicina asks, What does this new age mean for pharma?
Latest:
Driving Access to the Most Efficient Form of HealthcareA look at the pharmaceutical value chain and how pricing concerns and patient centricity fits in to improving access.
Latest:
Curing Big Pharma’s Litigation Spend Woes with Data-Driven MedicineDaniel Gold looks at the benefits of centralising an organization's data in a core repository and adopting a comprehensive business intelligence strategy.
Latest:
Creating Defensible Data Analytics Moats for a Competitive AdvantageKarim Damji discusses how Artificial Intelligence (AI)-informed Systems of Intelligence and Virtual Assistants offer powerful solutions to the common struggles pharma companies face today.
Latest:
Social Science Behavior Change Models: The Key to More Targeted MessagesBehavioral social scientists try to understand human behavior and find ways to make people accept and adapt it. Pharma sales and marketing is no different – especially with the launch of a new product, writes Charles Daramola.
Latest:
Navigating Unplanned Value Inflection Points in International AlliancesDealing with significant unplanned events in alliances is important work. It's is critical to maintain the ongoing health of the alliance by applying sound governance principles and minimizing the disruption to normal operations wherever possible. So how can you stabilize your ships in rough seas?
Latest:
The Genetic Data Gold Rush: Balancing Privacy and Health OutcomesAs pharm execs look to real-world data to aid in translational research and close the gap from traditional clinical trials to real-world efficacy, there are three foundational pillars to build from. Bill Fox reports.
